Victoria Rac - Bio Path Regulatory Consultant
| BPTH Stock | USD 0.06 0 5.00% |
Insider
Victoria Rac is Regulatory Consultant of Bio Path Holdings
| Phone | 832 742 1357 |
| Web | https://www.biopathholdings.com |
Bio Path Management Efficiency
The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Dan Slonim | Orgenesis | N/A | |
| Vincent Vandamme | Orgenesis | N/A | |
| Efrat Kunik | Orgenesis | 49 | |
| Kelly Forsythe | Helix BioMedix | N/A | |
| Neil CPA | Orgenesis | 54 | |
| Pr Ferber | Orgenesis | 70 | |
| Evan Fishman | Orgenesis | N/A | |
| Shimon Hassin | Orgenesis | N/A | |
| Vered MSc | Orgenesis | 55 | |
Management Performance
| Return On Equity | -11.6 | |||
| Return On Asset | -1.94 |
Bio Path Holdings Leadership Team
Elected by the shareholders, the Bio Path's board of directors comprises two types of representatives: Bio Path inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Path's management team and ensure that shareholders' interests are well served. Bio Path's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Path's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan MacKenzie, Consultant | ||
| Thomas Walker, Consultant | ||
| MBA Ashizawa, Development Research | ||
| Michael MBA, VP Operations | ||
| Peter MBA, Chairman, CoFounder | ||
| Jeffery MD, Consultant | ||
| Victoria Rac, Regulatory Consultant | ||
| Anthony Price, Accounting Finance | ||
| Douglas Morris, Co-Founder and Director | ||
| MBA MBA, Development Research | ||
| Anthony MBA, Accounting Finance |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Bio Path a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.6 | |||
| Return On Asset | -1.94 | |||
| Current Valuation | 531.06 K | |||
| Shares Outstanding | 5.77 M | |||
| Shares Owned By Institutions | 7.41 % | |||
| Number Of Shares Shorted | 79.35 K | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 2.33 X | |||
| EBITDA | (15.76 M) | |||
| Net Income | (16.08 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Bio OTC Stock
Bio Path financial ratios help investors to determine whether Bio OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Path security.